Pfizer, Inc. · NYSE:PFE

Pfizer — Guggenheim 3rd Annual Boston Healthcare Conference (December 2015)

13 slides from Pfizer's conference presentation, Dec 15, 2015

  1. Slide 1: Potentially Accelerating Transformative Medicines to Market

    Potentially Accelerating Transformative Medicines to Market Guggenheim 3rd Annual Boston Healthcare Conference Mikael Dolsten, M.D., Ph.D. President Worldwide R&D December 15, 2015

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements • This presentation includes forward-looking statements about, among other things, development of Pfizer’s products and product candidates, including their potential benefits, expected market opportunity and expected regulatory submissions and approvals that are subject to

  3. Slide 3: Strong Track Record of Approvals

    Strong Track Record of Approvals Over the last 5 years >25 Phase 3 starts & >15 key approvals (10 NME’s) 3

  4. Slide 4: Strong Track Record of Approvals: Pneumococcal Vaccine for All Age Groups

    Strong Track Record of Approvals Over the last 5 years >25 Phase 3 starts & >15 key approvals (10 NME’s) A Pneumococcal Vaccine for All Age Groups CAPiTA adult approval 4

  5. Slide 5: Strong Track Record of Approvals: Advanced Breast Cancer

    Strong Track Record of Approvals Over the last 5 years >25 Phase 3 starts & >15 key approvals (10 NME’s) Approved 1L Adv. Breast Cancer (BC) + Letrozole (US) Recurrent Adv. BC submission with priority review (US) Phase 3 Start in adjuvant early BC 5

  6. Slide 6: Strong Track Record of Approvals: Renal Cell Carcinoma

    Strong Track Record of Approvals Over the last 5 years >25 Phase 3 starts & >15 key approvals (10 NME’s) Approved for adv. renal cell carcinoma (RCC) Ph 3. Study Adjuvant RCC Ph. 1 Inlyta® + Keytruda® shows activity in naïve adv. RCC 6

  7. Slide 7: Strong Track Record of Approvals: ALK+ and ROS1+ NSCLC

    Strong Track Record of Approvals Over the last 5 years >25 Phase 3 starts & >15 key approvals (10 NME’s) Approved for ALK+ NSCLC ROS1+ NSCLC Submission with Priority Review (US) ROS1+ NSCLC Breakthrough Designation 7

  8. Slide 8: Strong Track Record of Approvals: Rheumatoid Arthritis

    Strong Track Record of Approvals Over the last 5 years >25 Phase 3 starts & >15 key approvals (10 NME’s) Approved for treatment of rheumatoid arthritis (RA) Ph. 3 studies Psoriatic Arthritis & Ulcerative Colitis QD MR NDA Submission (US) 8

  9. Slide 9: Strong Track Record of Approvals: Atrial Fibrillation and DVT/PE

    Strong Track Record of Approvals Over the last 5 years >25 Phase 3 starts & >15 key approvals (10 NME’s) Approved for Prevention Atrial Fibrillation Approved for Treatment of DVT & PE 9

  10. Slide 10: Robust Pipeline Positioned to Sustain Productivity

    Robust Pipeline Positioned to Sustain Productivity Pfizer Pipeline (As of October 27, 2015) 214 Discovery Discovery Projects Phase 1 Phase 2 Phase 3 Registration 84 Projects 30 20 26 8 Total ~50% biologics, biosimilars and vaccines Programs with Accelerated Regulatory Pathways 3 6 14 Breakthrough Fa

  11. Slide 11: Delivering Novel & Differentiated Future Potential Products

    Delivering Novel & Differentiated Future Potential Products Potential for >20 Approvals 2016-20, incl. 7 NMEs Oncology Vaccines Neuroscience Inflammation & Rare Disease CVMed Biosimilars Immunology Ibrance® Nosocomial Parkinson’s Sickle Cell Hyperlipidemia Xeljanz ® LCM rivipansel rituximab Breast C

  12. Slide 12: Delivering Novel & Differentiated Future Potential Products

    Delivering Novel & Differentiated Future Potential Products 6 Near-Term Growth Platforms with Potential for Significant Market Opportunity Ibrance® Beyond Breast Ca. Accelerating Nosocomial Lead in Class & Continued I/O Momentum Vaccines to Market Neuroscience Assets ONCOLOGY VACCINES NEUROSCIENCE L

  13. Slide 13: Q&A

    Q&A

Pfizer — Guggenheim 3rd Annual Boston Healthcare Conference (December 2015) on 6ix